April 2022 Top Biopharma Deal: Harbour BioMed – AstraZeneca Bispecific Antibody for Cancer Treatment
April 2022 Top Biopharma Deal Upfront
Harbour BioMed development and commercialization deal with AstraZeneca for solid tumors
Highlighted Deal Financial Comps
Date Announced:
April 6, 2022
Total Deal Value:
$350M
Upfront Cash:
$25M
Upfront Equity:
n/a
Option Payments:
n/a
Total Milestones:
up to $325M
Royalties:
Undisclosed tiered royalties
Cost & Profit Split:
n/a
Deal Synopsis
The Asset:
Harbour BioMed’s HBM7022 CLDN18.2xCD3 bispecific antibody for solid tumors, including gastric and pancreatic cancers
Deal Structure:
Development and Commercial License
Partnership Features:
Collaborative Development, No Shared Cost
Deal Details:
- Harbour BioMed granted AstraZeneca exclusive, worldwide rights to develop and commercialize its HBM7022 CLDN18.2xCD3 bispecific antibody developed using HBM’s HCAb based Immune Cell Engagers (HBICE) platform for the treatment of solid tumors, including gastric and pancreatic cancer.
- AstraZeneca will be responsible for all costs for development and commercialization.
- HBM will receive $25M up front and is eligible for up to $325M in development, regulatory, and commercial milestones, plus undisclosed tiered royalties.
Last Month:
Congrats to Harbour BioMed and AstraZeneca for landing DealForma’s April 2022 Top Biopharma Deal. Last month’s Deal of the Month was IGM Biosciences – Sanofi IgM antibody platform for Cancer and immunology/inflammation treatment. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
20,378
Licensing Deals
17,730
Funding Rounds
4,034
M&A
31,012
Company Profiles
5,478
Other Deals
26,505
Drug Sales Figures
All of this by stage, disease indication, modality, target...
More Research by DealForma
Introducing: DealForma plus Tableau
We are excited to introduce DealForma's new Tableau dashboard integration. High quality data on biopharma deals and funding meets interactive charts and visuals. DealForma customers will have exclusive access to the DealForma chart dashboards built on Tableau right...
Venture & IPO – Medtech – Q1 2023
The Medtech sector encompasses medical devices, diagnostics, and digital health solutions, playing a crucial role in healthcare. In Q1 2022, the medtech, devices, digital health therapeutics, and wearables sector experienced a strong opening with 95 funding rounds and...